tbuckley/cabot-search huggingface dataset:
Aumento explosivo de Salmonella Java en productos avícolas y carne de ave de los Países Bajos: consecuencias para la salud pública
Authors: W van Pelt, H van der Zee, W J B Wannet, A. W van de Giessen, D. J Mevius, N M Bolder, Y T H P van Duynhoven
Journal: Eurosurveillance (2003)

En los Paises Bajos, la presencia de Salmonella Paratyphi B serotipo Java en las aves de corral aumento de menos de un 2% de todos los aislamientos anteriores a 1996, al 60% en 2002. Pese a la elevada exposicion a carne contaminada, los pacientes humanos con infeccion por Java son poco frecuentes (0,3% de todos los aislamientos). Sin embargo, un 50% de los aislamientos humanos mostraron perfiles PFGE identicos a los del clon aviar. La resistencia de S. Java al flumequino aumento del 3% entre 1996-2000 al 19% en 2001, y al 39% en 2002, mientras que la de otros serotipos en las aves de corral se mantuvo en el 7%. S. Java tambien esta perdiendo rapidamente la sensibilidad al ciprofloxacino.
Nouvelle situation épidémiologique des infections à méningocoque en Belgique
Authors: F Carion, M van Looveren, H Goossens
Journal: Eurosurveillance (1997)

En Belgique, apres l'epidemie survenue au debut des annees 1970 et causee par Neisseria meningitidis B:2b:P1.2 (les incidences les plus elevees se sont produites en 1971 et 1972 avec 5 cas pour 100 000 habitants par an), l'incidence des infections a meningocoque est revenue a des proportions interepidemiques normales de 1/100 000 par an. Pourtant, depuis le debut des annees 1990, l'incidence annuelle des infections a progressivement augmente jusqu'a 2/100 000. Le nombre total des isolements recus au laboratoire du centre national de reference est passe de 96 en 1991 a 210 en 1996. La plupart des cas sont apparus au nord de la Belgique : une recrudescence constante des infections a meningocoque a ete observee dans la province d'Anvers en 1993 et dans la partie ouest des Flandres en 1995.
Nitroxoline in geriatric patients with lower urinary tract infection fails to achieve microbiologic eradication: a noncomparative, prospective observational study
Authors: C. Forstner, A. Kwetkat, O. Makarewicz, A. Hartung, W. Pfister, R. Fünfstück, E. Hummers-Pradier, K.G. Naber, S. Hagel, N. Harrison, U. Schumacher, M.W. Pletz
Journal: Clinical Microbiology and Infection (2017)
P2.01-022 Nintedanib/Docetaxel Efficacy in Advanced Lung Adenocarcinoma Treated with 1L Chemotherapy/2L Immunotherapy in Nintedanib NPU
Authors: J. Corral, M. Majem, D. Rodríguez-Abreu, E. Carcereny, A. Artal Cortes, M. Llorente, J.M. López Picazo, Y. García, M. Domine, M.P. Lopez Criado
Journal: Journal of Thoracic Oncology (2017)
ATIM-21. INTRAVENOUS DELIVERY OF TOCA 511 IN PATIENTS WITH HIGH GRADE GLIOMA RESULTS IN QUANTIFIABLE EXPRESSION OF CYTOSINE DEAMINASE IN TUMOR TISSUE
Authors: Tobias Walbert, Daniela Bota, Michael Vogelbaum, Steven Kalkanis, Linda Liau, Tom Mikkelsen, Harry Gruber, Jolene Shorr, Maria Rodriguez-Aquirre, Derek Ostertag, Leah Mitchell, Douglas Jolly, Timothy Cloughesy
Journal: Neuro-Oncology (2017)

Toca 511 (vocimagene amiretroprepvec) is an investigational, conditionally lytic, retroviral replicating vector that encodes an optimized yeast cytosine deaminase (CD) gene. The CD gene converts the prodrug, Toca FC (investigational, extended-release 5-fluorocytosine), into the chemotherapeutic, 5-FU in infected tumors. In a Phase 1 study (NCT01985256), Toca 511 was injected intravenously for 1, 3, or 5 days to patients with recurrent high grade glioma. Tumors were subsequently resected, and Toca 511 was injected into the resection cavity walls. At the time of resection, tissue from various regions of the tumor was collected and processed for quantitative PCR analysis of CD RNA and DNA. Tissue from corresponding locations was fixed for assessment of CD protein expression by immunohistochemistry (IHC). Expression of CD protein was quantified based on immunofluorescence signal and was shown to co-localize in cells with detectable levels of gag, a viral structural protein. CD protein expression by IHC was assessed in tissue from locations that corresponded with samples positive for CD by PCR and ranged from 1.16% to 10.4% area of the field. These data show that intravenous delivery of Toca 511 results in appreciable deposition of vector in the tumor. Further, we have observed an inverse correlation between T cell infiltrate in the tumor microenvironment and clinical benefit in a complementary Phase I study in which Toca 511 was solely delivered into the resection cavity. Therefore, the nature of the study design described herein, which uses IV delivery of Toca 511, provides a unique opportunity to assess the spatial relationship between CD protein expression and histological features of the tumor. Immunohistochemical assessment to determine spatial correlates between CD protein and T cells, T regulatory cells, and immunosuppressive myeloid cells will be presented. Updated clinical response data will also be presented.
IMMU-19. QUANTITATION AND CHARACTERIZATION OF GLIOBLASTOMA-ASSOCIATED MICROGLIA AND MACROPHAGES REVEALS HIGHLY VARIABLE INFLAMMATORY PROFILES AND AN INVERSE RELATIONSHIP TO PERITUMORAL EDEMA VOLUME
Authors: Candice C Poon, Runze Yang, Katherine Liu, Susobhan Sarkar, Reza Mirzaei, V Wee Yong, John Kelly
Journal: Neuro-Oncology (2017)

Innate immune cells in the CNS, microglia and macrophages (MMs), are the largest component of the inflammatory infiltrate in glioblastoma (GBM). They initially participate in tumor surveillance, but are co-opted by GBM to adopt anti-inflammatory, immunosuppressive phenotypes and aid neoplastic progression. The bulk of immunotherapy research in GBM has been directed at T cells, which are part of the adaptive immune system, but make up a much smaller part of the inflammatory infiltrate. An effective immunotherapy against GBM has still not been found, in part because of a lack in understanding of GBM-associated MMs and the way they affect the immune microenvironment in which T cell therapies are expected to work. Our studies on human GBM tissue have uncovered there is surprisingly marked variation in the amount of MM infiltration between tumors, and this has bearing on clincopathologic parameters. Using automated quantitation methods, immunohistofluorescence, and validation with flow cytometry, we found that MM infiltration can range from almost non-existent, to comprising approximately 70% of GBM cells. With canonical markers and conditioned media, we determined that a mixture of pro-inflammatory and anti-inflammatory MMs were found in each tumor. Despite having a similar level of infiltration, GBM-associated MMs could still have drastically different gross inflammatory profiles. Age at diagnosis, time to progression, overall survival, comorbidities, and tumor volume were not associated with extent of MM infiltration. However, volumetric MRI analysis revealed heavier MM infiltration correlated with decreased peritumoral edema, contrary to previous reports. Taken together, we have found the inflammatory nature of the immune infiltrate can be drastically different between GBMs, and can have clinically significant effects on parameters such as peritumoral edema. These findings also demonstrate the importance of tailoring immunotherapies to individual patients given the considerable variability in magnitude and immunosuppression of the innate immune cells in the GBM microenvironment.
Mechanisms by which a Very-Low-Calorie Diet Reverses Hyperglycemia in a Rat Model of Type 2 Diabetes
Authors: Rachel J. Perry, Liang Peng, Gary W. Cline, Yongliang Wang, Aviva Rabin-Court, Joongyu D. Song, Dongyan Zhang, Xian-Man Zhang, Yuichi Nozaki, Sylvie Dufour, Kitt Falk Petersen, Gerald I. Shulman
Journal: Cell Metabolism (2017)
PATH-12. CLINICAL, MOLECULAR AND RADIOLOGICAL FEATURES OF FGFR-TACC POSITIVE GLIOMAS
Authors: Anna Luisa Di Stefano, Julien Savatovsky, Franck Bielle, Agusti Alentorn, Alberto Pïcca, Edouard Saragoussi, Chiara Villa, Patrizia Farina, Anna Lasorella, Antonio Iavarone, Marc Sanson
Journal: Neuro-Oncology (2017)

Activable oncogenic fusion between FGFR and TACC genes are found in 3% of glioblastoma. Overall, we screened 907 gliomas by RT-PCR for FGFR3-TACC3 fusions (655 grade IV, 144 grade III and 108 grade II) and identified 40 patients harboring FGFR3-TACC3 rearrangements so far. Clinical, molecular and radiological features are presented. We found that FGFR3-TACC3 fusions exclusively affect IDH wild-type gliomas (3%), and are mutually exclusive with the EGFR amplification and the EGFR vIII variant, whereas it co-occurs with CDK4 amplification, MDM2 amplification and 10q loss. FGFR3–TACC3 fusions are associated with strong and homogeneous FGFR3 immunostaining. To determine sensitivity and specificity of FGFR3 immunostaining to predict the presence of FGFR3-TACC3 fusions we analyzed a prospective cohort of 236 subjects using parallel-blinded immunostaining and RT-PCR assay. Sensitivity of FGFR3 immunostaining to predict the FGFR3-TACC3 fusions is 100%, specificity 81.8%, positive predictive value 19.6% and negative predictive value 100%. We compared overall survival from time of diagnosis of FGFR3-TACC3 positive patients with the IDH wild-type glioma of this cohort. Survival is significantly longer in FGFR3-TACC3 patients than FGFR3-TACC3 negatives (median OS 40.1 and 20.0 months respectively) (P=0.03) and this difference is stronger in the grade IV subgroup (median OS FGFR3-TACC3 positives 40.1 months versus FGFR3-TACC3 negatives OS 19.0; P=0.006). Preliminary observation suggest that FGFR3-TACC3 gliomas present more frequently in unifocal and cortical location with pial invasion. We are conducting a case-control radiogenomic analysis (25 cases and 50 controls): results will be discussed further.
Immunogenicity and safety of one versus two doses of tetravalent dengue vaccine in healthy children aged 2–17 years in Asia and Latin America: 18-month interim data from a phase 2, randomised, placebo-controlled study
Authors: Xavier Sáez-Llorens, Vianney Tricou, Delia Yu, Luis Rivera, José Jimeno, Ana Cecilia Villarreal, Epiphany Dato, Sonia Mazara, Maria Vargas, Manja Brose, Martina Rauscher, Suely Tuboi, Astrid Borkowski, Derek Wallace
Journal: The Lancet Infectious Diseases (2017)
Lettre à la Rédaction : Epidémies de parvovirus B19
Authors: B J Cohen
Journal: Eurosurveillance (2005)

In response to the recent report of school outbreaks of parvovirus B19 infection in Portugal [1], Heath Kelly and Jennie Leydon of the Western Pacific Regional Measles Laboratory, have echoed the call for parvovirus B19 tests to be included in measles and
P1.07-025 Correlating ISEND and Tumor Mutation Burden (TMB) with Clinical Outcomes of Advanced Non-Small Cell Lung Cancer (ANSCLC) Patients on Nivolumab
Authors: W. Park, G. Lopes, D. Kwon, V. Florou, Y.K. Chae, J. Warsch, A. Ishkanian, M. Jahanzeb, R. Mudad
Journal: Journal of Thoracic Oncology (2017)
RARE-05. PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA IN IMMUNOCOMPROMISED HOSTS – A SINGLE INSTITUTION RETROSPECTIVE STUDY (2002-2017)
Authors: Leon Kaulen, Daniela Galluzzo, Pei Hui, Anita Huttner, Robert Fulbright, Joachim Baehring
Journal: Neuro-Oncology (2017)

Congenital or acquired immunodeficiency is a major risk factor for primary central nervous system lymphoma (PCNSL), but studies rarely focus on disease in immunocompromised hosts. We aimed to define clinical and imaging features and determine prognostic factors for PCNSL in the immunocompromised host. All 120 biopsy confirmed PCNSL cases seen at Yale-New Haven Hospital between 2002 and 2017 were retrospectively screened for primary or acquired immunodeficiency. Biopsies were again reviewed by a single pathologist and clinical, imaging, other diagnostic data, treatment and outcome data were reviewed. Predictors of survival were identified using Kaplan-Meier survival analysis and log-rank test (GraphPad Prism software). P values < 0.05 were considered significant. Twenty-three patients with acquired immunodeficiencies were included: eleven with central nervous system post-transplant lymphoproliferative disorder (CNS PTLD), seven with human immunodeficiency virus (HIV) infection, and five patients with long term immunosuppressive treatment due to various autoimmune disorders (AID). All subgroups shared distinct clinical features that distinguished them from PCNSL in the immunocompetent host: they were largely Epstein-Barr-Virus (EBV) positive (PTLD: 91%, HIV: 71%, AID: 60%), histologically classified as diffuse large B-cell lymphomas (PTLD: 73%, HIV: 100%, AID: 80%) and showed peripheral enhancement on MRI (PTLD: 73%, HIV: 71%, AID: 60%). Overall median survival was 31 months (PTLD: 16 months, HIV: 26 months, AID: 98 months). Age over 60 years at pathological diagnosis was identified as a negative prognostic factor (p < 0.01). Patients with peripheral enhancement on MRI also showed significantly shorter overall survival (p < 0.05). PCNSL in immunocompromised hosts presents with similar clinical and imaging features suggesting a common EBV driven pathogenesis. Differences in survival may reflect severity of comorbidities. Age over 60 years and ring enhancement on MRI may serve as predictors of less favorable outcome.
P3.09-007 Thoracic Asymmetry and Its Impact on Survival after Radiation and Surgery for Malignant Pleural Mesothelioma
Authors: J. Cho, P. Bradbury, D. Patsios, S. Keshavjee, N. Leighl, A. Hope, M. De Perrot
Journal: Journal of Thoracic Oncology (2017)
Utilización del virus de la viruela como arma biológica: la situación vacunal en Francia
Authors: D Lévy-Bruhl, N Guérin
Journal: Eurosurveillance (2001)

En el contexto de su plan de lucha contra el bioterrorismo, el Ministerio de Salud Frances solicito al Instituto de Vigilancia de la Salud (Institut de Veille Sanitaire; InVS) una evaluacion del riesgo de epidemia como consecuencia de la introduccion del virus de la viruela, y la formulacion de recomendaciones en materia de eventuales estrategias de vacunacion que pudieren ponerse en practica. Se evaluaron los beneficios/riesgos ofrecidos por distintos escenarios de vacunacion, incluyendo el de toda la poblacion francesa, para distintos niveles de intensidad de una amenaza de accion terrorista. En este analisis se llega a la conclusion de que la situacion actual no justifica una campana de vacunacion. Incluso en el caso de una amenaza real, la vacunacion del personal sanitario de primera linea y, especialmente, la de los contactos de los casos, constituirian las estrategias prioritarias.
Vigilancia de la resistencia antimicrobiana en Bulgaria – una sinopsis de BulSTAR 2003
Authors: M Petrov, N Hadjieva, T Kantardjiev, Tz Velinov, A Bachvarova
Journal: Eurosurveillance (2005)

El articulo siguiente presenta el sistema de vigilancia de la resistencia antimicrobiana en Bulgaria (Bulgarian Surveillance Tracking Antimicrobial Resistance, BulSTAR) y los datos de vigilancia de 2003. Este programa de vigilancia longitudinal se encarga del aislamiento y de la sensibilidad a los antibioticos de todos los micro-organismos que tienen una importancia clinica, aislados por los laboratorios de microbiologia participantes a partir de cultivos sanguineos, liquido cefalorraquideo, las vias respiratorias altas y bajas, orina y muestras de heridas. En BulSTAR 2003 participaron 28 laboratorios publicos, 45 hospitalarios y seis privados en la totalidad de los 28 distritos de la Republica de Bulgaria. El numero total de aislamientos procedentes de fuentes controladas durante el periodo de estudio fue de 98.929. Siete micro-organismos representaron el 72% de todas las bacterias en BulSTAR 2003: Escherichia coli, Staphylococcus aureus, el grupo Proteus-Providencia-Morganella, Klebsiella spp., Pseudomonas spp, Streptococcus pneumoniae y Streptococcus pyogenes. La resistencia antimicrobiana de bacterias clinicas Gram positivas y Gram negativas en Bulgaria fue estimada de nivel medio comparada con otras fuentes de vigilancia en el mundo. Una experiencia unica en la poblacion sobre un periodo de 32 anos que consistia en tratar todas las infecciones graves con una combinacion de ampicilina y gentamicina, condujo a unas tasas de resistencia a los aminoglucosidos dos veces mas altas comparadas con otros paises del mundo. Esto es el resultado de esquemas terapeuticos extremadamente conservadores utilizados en los ex-paises socialistas, basados en directivas nacionales y una produccion interna de gentamicina y de ampicilina a bajo coste. La implementacion proxima de una red computerizada y las mejoras para la deteccion de los errores deberian aumentar la sensibilidad y el impacto del sistema de vigilancia BulSTAR, una herramienta indispensable en la lucha contra el fenomeno mundial de la resistencia antimicrobiana.
P3.02-068 95 Cases of EGFR/ALK Gene Status Analysis in Lung Adenosquamous Carcinoma
Authors: Z. Xu, C. Xu, W. Wang, Q. Xu, W. Zhuang, Z. Song, Y. Chen, G. Chen, M. Fang, T. Lv, Y. Song
Journal: Journal of Thoracic Oncology (2017)
ACTR-18. INTERFERON-ALPHA ENHANCES TEMOZOLOMIDE ANTI-GLIOMA EFFICACY: FROM BENCH TO BEDSIDE
Authors: Zhong-ping Chen, Qunying Yang, Chengcheng Guo, Dong Shen
Journal: Neuro-Oncology (2017)

O6-methylguanine DNA methyltranferase (MGMT) is one of the main mechanisms of chemoresistance for alkylating agents in malignant gliomas. Treatment for MGMT positive glioma is still challenge in clinical practice. We firstly tested anti-tumor efficacy of IFN-α combined with temozolomide (TMZ) in vitro and in vivo on 2 MGMT protein positive glioma cell lines. Then, we have launched a clinical trial “Adjuvant Temozolomide with Interferon-alpha in Newly Diagnosed High-grade Gliomas” (ClinicalTrials.gov ID:NCT01765088). The patients (WHO grade III/IV), received tumor resection and radiotherapy concurrent with TMZ, will be randomized assigning to receive up-to 12 cycles of standard TMZ chemotherapy alone or combined with IFN-α (3mIU on Day1,3,5 of each cycle). The proliferation analysis demonstrated that MGMT positive glioma stem cells (U251G and SKMG-4G), treated with TMZ or TMZ plus IFN-α resulted in inhibition rates of 16.13%±2.33% vis 57.95%±1.54% (U251G), and 57.74%±2.91%(SKMG-4G), respectively(p<0.05). The tumor growth repression rates of TMZ group, TMZ+IFN-α group on U251G xenografts were 16.7%±1.96% and 41.1%±8.66%，and on SKMG-4G xenografts were 35.2%±2.28% and 58.4%±4.34% respectively (Ρ<0.05). On clinical trail, 168 cases (WHO III, 81 cases and WHO IV, 87 cases) have been enrolled till March of 2016. Follow-up to end of 2016, 105 patients had tumor progression including 65 deaths. Survival analysis revealed that in grade III patients, OS and PFS in TMZ group and TMZ+ IFN-α group were 28 vis 36 months(p=0.16), and 16 vis 25 months(p=0.17), respectively; while in GBM patients, that were 24 vis 16 months(p=0.04), and 11 vis 9 months (p=0.17), respectively. Our results indicate that IFN-α could enhance anti-tumor efficacy of TMZ to high grade gliomas.
Une comparaison des sites internet des réseaux de surveillance des maladies dans l’Union Européenne
Authors: A Lenglet, G Hernández Pezzi
Journal: Eurosurveillance (2006)

Actuellement dans l’Union Europeenne (UE), la surveillance des maladies infectieuses est assuree par le Basic Surveillance Network (BSN) et par d’autres reseaux de surveillance specifiques de maladie (disease specific surveillance networks, DSN). Chaque reseau possede un site internet. L’etude suivante a pour objectif de decrire les informations presentees en libre acces sur chaque site internet, du point de vue de leur utilite en termes de surveillance d’un etat membre de l’UE. Ont ete inclus dans l’etude le BSN et les DSN cites dans la Decision Communautaire 2003/542/CE. Chaque site internet a ete examine et evalue au regard de caracteristiques de trois categories principales : 1) les informations generales, 2) les procedures de recueil de donnees et 3) la presentation des donnees. Les sites web ont ete visites la semaine du 5 decembre 2005. Dix sites de reseaux de surveillance ont ainsi ete analyses. 80% d’entre eux ont inclus la liste des pays participants, les adresses du coordinateur du reseau, les participants par pays et les objectifs du reseau. Seul un reseau precise la source et la couverture des donnees par pays et sept d’entre eux presentent la definition de cas de la maladie surveillee. Les donnees brutes sont disponibles sur huit sites et seuls deux reseaux ont inclus la presentation de donnees elaborees pour l’Europe entiere. Quatre reseaux n’ont pas de rapport accessible sur leur site. La periodicite des mises a jour, que ce soit pour les donnees brutes ou pour les donnees elaborees, est tres variable. 
De meme, les informations accessibles au public sur les dix sites des reseaux etudies sont heterogenes. Nous recommandons que tous les reseaux presentent sur leur site un ensemble de caracteristiques essentielles, dont les definitions de cas, les procedures utilisees pour le recueil de donnees et les rapports periodiques presentant les donnees elaborees pour l’ensemble de l’Union Europeenne.
TMOD-26. HUMAN GLIOBLASTOMA SLICE CULTURES AS A PLATFORM FOR IDENTIFICATION OF PATIENT-SPECIFIC DECREASE IN CELL MIGRATION AND RESPONSE TO THERAPY
Authors: Vashali Jain, Lauren Gardiner, Shiva Krishnan, Masood Sadaat, Jonathan Parker, Allen Waziri, Kara Foshay
Journal: Neuro-Oncology (2017)

Molecular heterogeneity in glioblastoma (GBM) is widely recognized at the inter-patient and intra-tumoral levels. More recently, we provided confirmation that endogenous heterogeneity also exists on a biological basis through analysis of migrating cells within ex vivo organotypic slice cultures from patients with primary GBM. These proof-of-principle studies demonstrated differential anti-invasive responses to gefitinib in slices from patients with or without EGFR amplification. Given these data, we concluded that greater insight into migrational heterogeneity may provide opportunities for personalized anti-invasive drug choices in GBM patients. To further explore this concept, we expanded upon the ex vivo slice culture paradigm to create a multi-drug testing platform that utilizes large-scale parallel analysis of slices from primary human GBM, through which we can visualize and screen across patients for effective reduction in cell migration in tightly controlled fashion. Using a panel of tyrosine kinase inhibitors chosen for their influence on migratory signaling pathways, preliminary data reveal differential responses from patient-to-patient across the drug spectrum. In some cases, up to a 30% reduction in migration speed were seen in response to specific drugs after short-term exposures. Critically, results from duplicate samples were consistent within tested individuals. These data suggest this model may be used to select patient-specific drug treatments based on modulation of a biologically important behavior and, while treatment variables such as drug concentration, length of treatment and combination strategies remain to be tested, we propose that this model may provide a preclinical stratification mechanism for identifying patient-specific anti-invasive therapies in GBM.